Interestingly, the marked ex vivo activity of DS/Cu was observed in CD34+ cells isolated from patients with sAML developed from MDS, without any significant difference compared with those from patients with primary AML, suggesting that patients with sAML might be also susceptible to DS/Cu treatment. This evidence concerns the gene CD34 and acute myeloid leukemia.